January 18, 2025 - 15:08

Start-ups with Chinese ties have found it increasingly difficult to do business and list shares in the United States. The escalating geopolitical tensions between the U.S. and China have created an environment of uncertainty for these companies. Many are reassessing their strategies as regulatory scrutiny intensifies, making it challenging to navigate the complex landscape of U.S. financial markets.
Chinese firms seeking to enter or expand in the U.S. market are now encountering heightened due diligence and potential barriers that were not as prevalent in previous years. This has led to a significant decline in initial public offerings (IPOs) for Chinese companies on American exchanges, as investors become more cautious and regulatory bodies tighten their oversight.
In light of these challenges, some Chinese start-ups are exploring alternative markets or reconsidering their business models to adapt to the evolving landscape. The situation underscores the growing divide between the two nations and the implications for global business dynamics.
August 21, 2026 - 08:33
National Federation of Independent Business in Ohio endorses Ramaswamy for Gov.The Republican contest for Ohio governor gained a notable endorsement Thursday evening when the National Federation of Independent Business threw its support behind Vivek Ramaswamy. The group,...
August 20, 2026 - 20:06
TAVR is safe for patients with large aortic annuli—heart failure remains a concernNew data suggest that transcatheter aortic valve replacement (TAVR) is a safe option for patients with large or extra-large aortic annuli, though the procedure does not eliminate the ongoing threat...
August 20, 2026 - 00:01
Better Business Bureau warns of fake grocery, gas vouchers that could cost customersThe Better Business Bureau is sounding the alarm over a new wave of fake vouchers arriving in mailboxes. The scheme involves postcards or flyers that promise significant savings on groceries and...
August 19, 2026 - 00:07
FDA wants feedback on how to regulate generative AI in medicineThe U.S. Food and Drug Administration is opening a formal comment period to gather perspectives on how it should regulate generative artificial intelligence used in medical devices. The move...